At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Market Closed 11-15 16:08:33
37.200
-0.500
-1.33%
High38.500Low36.800Vol6.22M
Open37.400D1 Closing37.700Amplitude4.51%
Mkt Cap60.61BTradable Cap60.61BTotal Shares1.63B
T/O232.40MT/O Rate0.38%Tradable Shares1.63B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
JPMorgan Chase & Co's Long Position in Shares of Innovent Biologics Decreases to 5.57% on Oct. 30 From 6.10% - HKEX
THOMSON REUTERS  ·  11-05
JPMorgan Chase & Co's Long Position in Shares of Innovent Biologics Decreases to 5.57% on Oct. 30 From 6.10% - HKEX
Innovent Biologics Terminates Share Subscription Agreement with Lostrancos Ventures
MT Newswires Live  ·  11-04
Innovent Biologics Terminates Share Subscription Agreement with Lostrancos Ventures
Stock Track | INNOVENT BIO Soars 13% After Terminating Agreement, Affirming Global Expansion Plans
Stock Track  ·  11-04
Stock Track | INNOVENT BIO Soars 13% After Terminating Agreement, Affirming Global Expansion Plans
Hong Kong Stocks Close Higher, XPeng Soars 8%
Market Watcher  ·  11-04
Hong Kong Stocks Close Higher, XPeng Soars 8%
BRIEF-Innovent Biologics Says Q3 Total Product Revenue Exceeded Rmb2.3 Billion
Reuters  ·  10-30
BRIEF-Innovent Biologics Says Q3 Total Product Revenue Exceeded Rmb2.3 Billion
Innovent Biologics - Q3 Total Product Revenue Exceeded RMB2.3 Bln
THOMSON REUTERS  ·  10-30
Innovent Biologics - Q3 Total Product Revenue Exceeded RMB2.3 Bln
Innovent Biologics, Inc.'s (HKG:1801) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures
Simply Wall St.  ·  10-29
Innovent Biologics, Inc.'s (HKG:1801) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-Il-23P19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients With Prior Inadequate Response to Il-17 Biologics
THOMSON REUTERS  ·  10-29
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-Il-23P19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients With Prior Inadequate Response to Il-17 Biologics
Stock Track | Innovent Bio Plunges Over 13% on Dilution of Stake in Unit
Stock Track  ·  10-28
Stock Track | Innovent Bio Plunges Over 13% on Dilution of Stake in Unit
Innovent Biologics Unit to Issue, Sell Over 12.8 Million Shares
MT Newswires Live  ·  10-28
Innovent Biologics Unit to Issue, Sell Over 12.8 Million Shares
Innovent Biologics - Lostrancos Ventures to Subscribe for 12.8 Mln New Series Pre-a Preferred Shares for $20.5 Mln
THOMSON REUTERS  ·  10-25
Innovent Biologics - Lostrancos Ventures to Subscribe for 12.8 Mln New Series Pre-a Preferred Shares for $20.5 Mln
Innovent Biologics - Deemed Disposal of Equity Interest in Unit
THOMSON REUTERS  ·  10-25
Innovent Biologics - Deemed Disposal of Equity Interest in Unit
Innovent Announces Phase 2 Clinical Study of Picankibart (Ibi112) in Chinese Patients With Ulcerative Colitis Met Primary Endpoint
THOMSON REUTERS  ·  10-17
Innovent Announces Phase 2 Clinical Study of Picankibart (Ibi112) in Chinese Patients With Ulcerative Colitis Met Primary Endpoint
Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline
MT Newswires Live  ·  10-14
Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline
BRIEF-Innovent And Ask Pharm Announce Strategic Collaboration For Limertinib, A Third-Generation Egfr Tki For The Treatment Of Lung Cancer
Reuters  ·  10-08
BRIEF-Innovent And Ask Pharm Announce Strategic Collaboration For Limertinib, A Third-Generation Egfr Tki For The Treatment Of Lung Cancer
Innovent Biologics Inc - Obtains Exclusive Commercialization Rights for Limertinib in Mainland China
THOMSON REUTERS  ·  10-08
Innovent Biologics Inc - Obtains Exclusive Commercialization Rights for Limertinib in Mainland China
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-Generation Egfr Tki for the Treatment of Lung Cancer
THOMSON REUTERS  ·  10-08
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-Generation Egfr Tki for the Treatment of Lung Cancer
Don't Ignore The Insider Selling In Innovent Biologics
Simply Wall St.  ·  10-06
Don't Ignore The Insider Selling In Innovent Biologics
BRIEF-Innovent Announces Nmpa Acceptance Of NDA For Picankibart For Treating Moderate To Severe Plaque Psoriasis
Reuters  ·  09-26
BRIEF-Innovent Announces Nmpa Acceptance Of NDA For Picankibart For Treating Moderate To Severe Plaque Psoriasis
Stock Track | Innovent Bio Soars on Approval of New Psoriasis Drug Picankibart
Stock Track  ·  09-26
Stock Track | Innovent Bio Soars on Approval of New Psoriasis Drug Picankibart
No data available

Introduction

Company Name.
INNOVENT BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
Issue price:
--